Loading patent…
AssigneeThe Regents of the University of California
InventorsKarsten Zengler, Ajit Varki, Frederico Da Silva, Sandra Diaz, Cameron Martino, Geoffrey Chang, Steven Rees, Livia Soares Zaramela
Estimating the term…
The present disclosure relates to novel sialidase enzymes having a preference for cleaving N-glycolylneuraminic acid (Neu5Gc) from glycoconjugates over cleaving N-acetyineuraminic acid (Neu5Ac). The present disclosure further provides the polypeptide of such novel sialidase and its catalytic pockets; the recombinant host cells expressing the same, as well as the enzymatic, pharmaceutical, and consumable compositions comprising such novel sialidases. Probiotic compositions comprising a bacterium that expresses the sialidase having a preference for Neu5Gc over Neu5Ac, and methods for removing Neu5Gc from consumable products are also provided. Also disclosed are methods for treating or preventing various diseases, disorders, and inflammatory conditions in a subject using the novel sialidases.
A composition for treating or preventing an inflammatory condition in a subject, comprising an effective amount of a sialidase, wherein said sialidase comprises an Asp-box comprising RIP/RLP motif and four Asp containing consensus sequences (Ser/Thr-Xaa-Asp-[Xaa]-Gly-XaaThr-Trp/Phe) electrostatically interact with the carboxylate groups of sialic acids, and wherein said sialidase cleaves N-glycolylneuraminic acid (Neu5Gc) from glycoconjugates over cleaves N-acetylneuraminic acid (Neu5Ac).
Dependencies are inferred from the claim text.